You didn’t require artificial intelligence to predict one thing about the largest conference of the year for healthcare investors, which took place in San Francisco last week—it was bound to rain.
Recursion, a biotech company utilizing machine learning for pharmaceutical advancements, made a strategic move during the event by introducing AI-powered drug discovery software in collaboration with tech behemoth Nvidia. Amidst the downpour, Recursion staff distributed black umbrellas branded with the company’s logo, adorned with vibrant cell images—a clever marketing tactic among several others employed by the company. This included hosting a satellite event featuring Jensen Huang, the renowned CEO of Nvidia, who has garnered celebrity status on Wall Street due to his company’s soaring stock performance driven by the increasing anticipation for AI technology, propelling Nvidia to a $1 trillion market capitalization, ranking sixth globally.
The sight of the square outside the long-standing venue of the J.P. Morgan Healthcare Conference, the Westin St. Francis, being filled with Recursion’s branded umbrellas was akin to witnessing the affirmation that AI was poised for its grand entrance. However, it was evident that not everyone was prepared to fully embrace this proclamation.
